Beeline Medicines

Summary active Updated Jul 2, 2026

This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.

Location Stamford, CT
Founded 2025
Latest Stage Series A
Total Raised $426.3M
Website https://beelinemedicines.com
Sector
biotech immunology

Investors

bain-capital series-a (2026)
bain-capital series-a-extension (2026)

Founders

Saqib Islam CEO

About

Beeline Medicines is a Stamford, Connecticut-based clinical-stage biotechnology company developing precision therapies for autoimmune and inflammatory diseases, led by CEO Saqib Islam (former SpringWorks Therapeutics CEO; SpringWorks was acquired by Merck KGaA for $3.9B in April 2025) 123. Beeline was originally formed in July 2025 as a Bain Capital Life Sciences-backed company that in-licensed five clinical programs from Bristol Myers Squibb, and publicly debuted on April 15, 2026 with a $300M Series A led solely by Bain Capital Life Sciences 123. On June 30, 2026, Beeline closed a $126.3M Series A extension from existing shareholders including Bain Capital, CPP Investments, and Bristol Myers Squibb, bringing the total Series A financing to $426.3M 45. The lead program, afimetoran, is a selective TLR7/8 inhibitor granted FDA Fast Track Designation for systemic lupus erythematosus, with Phase 2 data expected later in 2026 134.

Funding History

Date Round Amount Lead Co-investors
2026-06-30 Series A Extension $126.3M Bain Capital CPP Investments, Bristol Myers Squibb 45
2026-04-15 Series A $300M Bain Capital Life Sciences — 123

What Investors Say

No verified investor quotes available at this time.

What Founders Say

“The strong participation of our existing equity holders in this extension reflects deep conviction in the opportunity ahead of us to deliver life-changing treatment options.” — Saqib Islam, CEO, Beeline Medicines, June 30, 2026 45

Sources

  1. GlobeNewsWire, “Beeline Medicines Debuts to Deliver Category-Leading Precision Therapies for People Living with Autoimmune and Inflammatory Diseases,” April 15, 2026. https://www.globenewswire.com/news-release/2026/04/15/3274299/0/en/Beeline-Medicines-Debuts-to-Deliver-Category-Leading-Precision-Therapies-for-People-Living-with-Autoimmune-and-Inflammatory-Diseases.html↩↩↩↩

  2. BioSpace, “BMS makes a Beeline, bringing 5 assets to biotech’s $300M precision immunology debut,” April 15, 2026. https://www.biospace.com/business/bms-makes-a-beeline-bringing-5-assets-to-biotechs-300m-precision-immunology-debut↩↩↩

  3. Bain Capital, “Beeline Medicines Debuts to Deliver Category-Leading Precision Therapies for People Living with Autoimmune and Inflammatory Diseases,” April 15, 2026. Accessed May 2026. https://www.baincapital.com/news/beeline-medicines-debuts-deliver-category-leading-precision-therapies-people-living-autoimmune↩↩↩↩

  4. Beeline Medicines press release, “Beeline Medicines Announces Upsized Series A of $426.3 Million to Advance Category-Leading Autoimmune and Inflammatory Disease Portfolio,” June 30, 2026. Accessed July 2026. https://beelinemedicines.com/press-releases/beeline-medicines-announces-upsized-series-a-of-426-3-million-to-advance-category-leading-autoimmune-and-inflammatory-disease-portfolio/↩↩↩↩

  5. BioSpace, “Beeline Medicines Announces Upsized Series A of $426.3 Million to Advance Category-Leading Autoimmune and Inflammatory Disease Portfolio,” June 30, 2026. Accessed July 2026. https://www.biospace.com/press-releases/beeline-medicines-announces-upsized-series-a-of-426-3-million-to-advance-category-leading-autoimmune-and-inflammatory-disease-portfolio↩↩↩